TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03229616
Drug: Cyclophosphamide (CY)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
Study: NCT00569803
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of placebo solution (product ID: 224818-N000- 029)
Study: NCT01316341
Drug: BI10773
Approvals — FDA: no, EMA: no, PMDA: no
Description: patient to receive a tablet containing high dose BI10773 p.o. plus one placebo
Study: NCT01316341
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patient to receive two placebos
Study: NCT01316341
Drug: BI10773
Approvals — FDA: no, EMA: no, PMDA: no
Description: patient to receive a tablet containing low dose BI10773 p.o. plus one placebo
Study: NCT01058083
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, Oral, 0 mg, daily, 28 days
Study: NCT00708305
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride free toothpaste (0ppmF)
Study: NCT03491748
Drug: ETX0282
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Gelatin capsules
Study: NCT03491748
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Gelatin capsules
Study: NCT03180879
Drug: Test - RB ibuprofen acid orodispersible tablets
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: RB ibuprofen acid orodispersible tablets, 2 x 200 mg, single dose, oral.
Study: NCT03180879
Drug: Reference - RB Nurofen ibuprofen acid tablets
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: RB Nurofen ibuprofen acid tablets, 2 x 200 mg, single dose, oral.
Study: NCT03512197
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was provided as 25 mg soft gelatin capsules 8PC, was supplied as double-blind in blister packs and taken orally.
Study: NCT03512197
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Along with the study drug/placebo, chemotherapy was given as well: either Daunorubicin or Idarubicin and Cytarabine - all taken by i.v.
Study: NCT03180879
Drug: Comparator - Dolormin ibuprofen lysine tablets
Normalized name: Ibuprofen Lysine
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dolormin ibuprofen lysine tablets 2 x 342 mg (each 342 mg tablet contains 200 mg ibuprofen), single dose, oral.
Study: NCT00723424
Drug: AZD5672
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg, for 13 days
Study: NCT01466790
Drug: TMC435
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC435 will be administered as one oral capsule of 150 mg once a day.
Study: NCT00002740
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002740
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02923193
Drug: Medtronic IN.PACT (DCB)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The IN.PACT Admiral DCB is an over-the-wire (OTW) balloon catheter with a drug-coated balloon at the distal tip. The drug component, referred to as the FreePac™ drug coating, consists of the drug paclitaxel and the excipient urea. The device component physically dilates the vessel lumen by PTA, and the drug is intended to reduce the proliferative response that is associated with restenosis.
Study: NCT03514381
Drug: Patients starting a treatment with Doxorubicin and Ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 9 blood samples will be collected at each Cycle:~* Cycle 1 (Day 1-Day 2-Day 3)~* Cycle 2 (Day 1-Day 2-Day 3)
Study: NCT03438240
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Plus 50 µg fentanyl
Study: NCT02419729
Drug: Placebo of Estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of topical estrogen cream.
Study: NCT00926575
Drug: oral beclomethasone 17,21-dipropionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two tablets QID for 50 days
Study: NCT00926575
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two tablets QID for 50 days
Study: NCT01027364
Drug: rFIX
Normalized name: rFIXFc
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01381835
Drug: TMC435
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg capsule once daily for 7 days
Study: NCT01939301
Drug: Inhaled Nitric Oxide
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitric Oxide + oxygen
Study: NCT01939301
Drug: Sham
Normalized name: SHAMPOO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrogen + Oxygen
Study: NCT02762838
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All patients will receive methotrexate in a dose from 10 to 25 mg per week.
Study: NCT02762838
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients will receive folic acid in a dose of 5 mg per week.
Study: NCT00811421
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: MQ-placebo oral administration at the 1st, 2nd and 3rd Antenatal Clinic visit as IPTp
Study: NCT01258660
Drug: EE 0.03 mg/DRSP 3 mg/Metafolin + folic acid placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination EE/DRSP/ Metafolin \[0.030 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP) + 0.451 mg Metafolin\] given orally in a cyclic regimen for 24 weeks (6 cycles) in combination with folic acid placebo tablets (encapsulated). Each treatment cycle consisting of once daily hormone and Metafolin treatment for 21-days followed by once daily hormone free, Metafolin only regimen for 7 days. This phase was followed by 20 weeks (5 cycles) folate elimination phase consisting of oral administration of Yasmin alone.
Study: NCT01258660
Drug: EE 0.03 mg/DRSP 3 mg (Yasmin) + folic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yasmin \[0.030 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP)\] in combination with folic acid tablets 0.4 mg (encapsulated), given orally in a cyclic regimen for 24 weeks (6 cycles). Each treatment cycle providing once daily hormone and folic acid treatment for 21 days followed by once daily hormone free, folic acid only regimen for 7 days (encapsulated). This phase was followed by 20 weeks (5 cycles) folate elimination phase consisting of oral administration of Yasmin alone.
Study: NCT00495092
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine from 300 mg/d to 1200 mg/d or 15 mg/kg/d
Study: NCT03653663
Drug: Simvastatin 20 mg
Normalized name: simvastatin 20 MG
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects are treated with 20 mg simvastatin for 8 weeks
Study: NCT03653663
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects are treated with placebo for 8 weeks
Study: NCT01812538
Drug: DIC075V
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four single dose treatments:~* Placebo (normal saline)~* Moxifloxacin (positive control)~* DIC075V 37.5 mg~* DIC075V 75 mg~All subjects receive each of the 4 treatments.
Study: NCT04205929
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral) once daily for 30 days. Treatment to be started after 3 consecutive days of bleeding
Study: NCT01586338
Drug: Hylan G-F 20
Normalized name: hylan G-F 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection (pre-filled glass syringe)
Study: NCT00089895
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous; delivery to match eptifibatide to maintain blind
Study: NCT01040286
Drug: Flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.0 mg
Study: NCT00002499
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01885260
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 doses on alternate days during the first week and then once weekly for 12 weeks
Study: NCT00003495
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with Stage IV or Recurrent Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT01447849
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills twice a day for one week.
Study: NCT00002502
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02778399
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets for oral administration once daily
Study: NCT02778399
Drug: OBE2109
Approvals — FDA: no, EMA: no, PMDA: no
Description: OBE2109 tablets for oral administration once daily
Study: NCT00004202
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01263106
Drug: LY2216684
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18-mg LY2216684 oral dose
Study: NCT01263106
Drug: Theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200-mg theophylline oral dose
Study: NCT01364974
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT00101998
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04306146
Drug: CAD-9303
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules filled with CAD-9303 from 3 mg up to 1000 mg.
Study: NCT04306146
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules
Study: NCT02714608
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator: Placebo. Dosage form:pill. Dosage :20pills ( only placebo ). Frequency:two times per day. Duration: until disease progression or death.
Study: NCT00543868
Drug: MK0782
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03855176
Drug: Vaqta Injectable Product
Normalized name: Vaqta Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive vaccine against hepatitis A virus
Study: NCT02611830
Drug: Placebo SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vedolizumab subcutaneous injection placebo
Study: NCT02215733
Drug: ARB
Normalized name: Arbli
Approvals — FDA: no, EMA: no, PMDA: no
Description: other than telmisartan
Study: NCT02215733
Drug: ACEI
Normalized name: Veneno de Abeja Aceite de Vibora
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02215733
Drug: Beta-blockers
Normalized name: BETA-BLOCKERS,TOPICAL OPHTHALMIC
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02215733
Drug: Diuretics
Normalized name: DIURETICS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04360785
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients randomized in this arm will have one subcutaneous injection of methotrexate 15min before and one 24h after their first injection of adalimumab prescribed as usual
Study: NCT01246180
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: diclofenac 5% vs placebo (topical application) cutaneous blood flow measurement using laser Doppler
Study: NCT01246180
Drug: Amiloride
Normalized name: Amiloride
DrugBank: Amiloride (DB00594)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amiloride 1mM vs placebo (intradermal injection) cutaneous blood flow measurement using laser Doppler
Study: NCT00568698
Drug: Placebo to match hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02895360
Drug: BAL101553
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAL101553 48-hour infusion on day 1, 8, and 15 of each 28-day cycle; oral capsule daily for one week during Cycle 2 (study days 15-21)
Study: NCT02412449
Drug: AKB-6548 tablet, reference formulation given in the fasted state
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02412449
Drug: AKB-6548 tablet, test formulation given in the fasted state.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02412449
Drug: AKB-6548 tablet, test formulation given in the fed state
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00583271
Drug: 98% dehydrated alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10ml of 98% dehydrated alcohol injected into the celiac ganglion during the EUS-CB
Study: NCT04072705
Drug: General principles of care and judgement of researcher
Normalized name: Betagen brand of Betamethasone and Gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Because our study will be performed by observational design, there will be no intervention for our study. Because it is a registry-based study, overall decision making for medications will be performed according to the general principles of care and judgement of researcher.
Study: NCT03712449
Drug: BOTOX Cosmetic®
Approvals — FDA: no, EMA: no, PMDA: no
Description: BOTOX Cosmetic, 20 U to glabellar lines and/or 2-6 U injected bilaterally to crow's feet lines and/or 24 U injected to forehead lines at Month 9 and Month 10 (BELKYRA Treatment) and at Month 3 and Month 4 (Non-BELKYRA Treatment).
Study: NCT00415701
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone 100 mg/2 ml: day of operation 3x, POD 1 2x, POD 2 1x
Study: NCT00415701
Drug: NaCl 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 0.9% 2 ml; day of operation 3x, POD 1 2x, POD 2 1x
Study: NCT04109742
Drug: phosphatidylcholine-curcumin complex supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: a dietary curcumin supplement given at two different doses
Study: NCT02918929
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo to match EDP 305
Study: NCT00479089
Drug: ZD1839
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg by mouth daily, without break.
Study: NCT03158389
Drug: APG101
Approvals — FDA: no, EMA: no, PMDA: no
Description: weekly i.v.
Study: NCT02165397
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo capsules orally.
Study: NCT03297398
Drug: Group-1 (15mg, OPK-88004)
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15mg, OPK-88004
Study: NCT03297398
Drug: Group-2 (25 mg,OPK-88004)
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg,OPK-88004
Study: NCT03430050
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule. Manufactured to mimic progesterone 200mg capsule.
Study: NCT03016598
Drug: Intranasal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each Veteran with a stimulant use disorder, receiving MMT for OUD will receive a placebo nasal spray 40IU to be self administered twice daily over 6 weeks while in the MMT program. The veteran will come in for a total of 7 weekly visits. At baseline and during the last visit the veteran will complete at Trier Social Stress Test (TSST), and psychophysiological and biomarkers of stress will be collected. At every weekly visit a urine sample and self-reported drug use will be collected and therapy attendance will be recorded.
Study: NCT01113671
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: includes inactive Ingredients
Study: NCT03757078
Drug: Relief Pro rectal suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relief Pro rectal suppositories: 1.0 mg Fluocortolone + 40 mg Lidocaine; Administration according to clinical practice
Study: NCT03548493
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl will be given to the active comparator group in a dose of 1 μg /kg IV bolus over 15 minutes followed by continuous infusion starting at 0.5 μg /kg/h
Study: NCT01648595
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In case group, 50 micrograms fentanyl was prescribed in two doses with an interval of 1 hour after being diluted in 4 cc normal saline
Study: NCT01963715
Drug: IMGN289
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00900783
Drug: FV-100 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily, for seven days
Study: NCT04424875
Drug: 3 mg melatonin
Normalized name: melatonin 3 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patients will remove impacted third molar and receive 3 mg melatonin into 2 ml hydroxyethyl cellulose gel 2%
Study: NCT04424875
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will remove impacted third molar and receive 2 ml hydroxyethyl cellulose gel 2%
Study: NCT00965120
Drug: Placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic infusion of placebo (saline).
Study: NCT02143141
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo in an equal volume to that of duramorph 150 mcg given with spinal anesthetic, then receipt of oral acetaminophen 1000mg during first 24 hours postoperatively. evaluation postoperative day 1 for measurement of itching, nausea, vomiting, pain and itching.
Study: NCT02780505
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active (ascorbic acid 250 mg) and placebo (same weight of starch) tablets were similar in shape and size for both study and control groups. Intravenous intervention was not advantageous for hemodialysis subjects and it was impossible for PD patients, therefore, oral administration was used. All follow-up records were stored.~The erythropoietin (EPO) injections was prescribed for each patient in weekly dose, started one month before collecting blood samples for vitamin C measurement.
Study: NCT00561899
Drug: intermittent preventive treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SP(500mg sulfadoxine/25mg pyrimethamine)1.25mg SP per kg stat Amodiaquine (200mg base) 25mg/kg over 3 days Piperaquine (320 mg per tablet) 16.8 g/kg daily for 3 days Du-Cotecxin ( 40mg dihydroartemisinin(DHA)/320mg piperaquine(PQP))PQP/DHA 1.6/12.8mg/kg once daily for 3 days
Study: NCT00005946
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00451828
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40mg/day
Study: NCT02602483
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02602483
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00458393
Drug: daily TDF/FTC
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily oral medication
Study: NCT00458393
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily oral medication
Study: NCT00226122
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin capsules 50 mg
Study: NCT00832000
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo three times a day; in pill form
Study: NCT04718233
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo will be administered orally in patients with recurrent pregnancy loss
Study: NCT03562429
Drug: TGFP
Normalized name: Transforming Growth Factor-Beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: TGFP is 1/20 concentration of Hu-Qian Wan (HQW). HQW is composited of 10 herbs, Chinemys reevesii (Gray), Phellodendron chinense Schneid., Achyranthes bidentata Blume, Anemarrhena asphodeloides Bunge, Rehmannia glutinosa Libosch., Paeonia lactiflora Pall., Cynomorium songaricum Rupr., Angelica sinensis (Oliv.) Diels, Citrus reticulata Blanco and Zingiber officinale Rosc..
Study: NCT00507221
Drug: Current standard of care in Kenya
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current standard of care for HIV patients in Kenya based on WHO guidelines.
Study: NCT02342145
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate was used 15mg/m2 on +1d and 10mg/m2 on +3,+6,+11d by intravenous for prevention of graft-versus-host-disease.
Study: NCT01233609
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage per subject weight- same schedule as the active comparator
Study: NCT01046422
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, Oral, 0mg, Daily, 28 days
Study: NCT04197479
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching tablets
Study: NCT01101061
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection
Study: NCT02033473
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A clamp reference during which a placebo solution (saline solution) will be administered
Study: NCT03819270
Drug: LY3372689
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT03819270
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00263575
Drug: EN3267
Approvals — FDA: no, EMA: no, PMDA: no
Description: EN3267 will be available in 100, 200, 300, 400, 600 (two 300 ug tablets), and 800 ug (two 400 ug tablets) doses
Study: NCT04340856
Drug: Laxatives
Normalized name: LAXATIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: There are no guidelines to direct laxative measures in patients with chronic megacolon. Historically, it is the gastroenterologists individual choice to use one of the above mentioned laxative measures. Therefore, the aim of this study is to analyze the success and downsides of the different Laxative measures.
Study: NCT01114308
Drug: placebo implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant contains ethylene vinyl acetate
Study: NCT01639794
Drug: Vesitirim™ (Solifenacin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT05809336
Drug: Inosine 0.2g orally 3 times/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: inosine + PD-1/PD-L1 inhibitor ± chemotherapy/targeting,